Orthostatic Intolerance Management
Orthostatic intolerance—including postural orthostatic tachycardia syndrome (POTS), neurally mediated hypotension (NMH), and orthostatic hypotension—affects an estimated 50–70% of ME/CFS patients (Chapter Cardiovascular Dysfunction). Orthostatic intolerance is a major contributor to functional limitation and a frequent cause of PEM when patients stand beyond their tolerance.
1 Non-pharmacological Approaches
Non-pharmacological management is the foundation of orthostatic intolerance treatment and should be implemented before or alongside medications. A qualitative study by Uppal et al. (2026, Raj lab) found that POTS patients in their sample consistently reported modest medication effectiveness and valued non-pharmacological strategies (salt loading, compression garments, exercise within tolerance) as core components of their management (Uppal et al. 2026). Most patients had tried multiple medications with limited benefit — underscoring the importance of realistic expectations and that non-pharmacological strategies are essential complements, not alternatives, to pharmacotherapy. Qualitative studies capture patient experience, which may reflect suboptimal dosing, poor specialist access, or early discontinuation from side effects in addition to genuine pharmacodynamic limitation; these findings are formative rather than confirmatory regarding medication effectiveness.
- Fluid and salt intake: 2–3 liters of fluid and 6–10 g of sodium chloride daily (unless contraindicated by renal or cardiac disease). Electrolyte solutions (oral rehydration salts) are more effective than water alone for plasma volume expansion. Salt tablets may be needed if dietary salt is insufficient
- Compression garments: Waist-high compression stockings (30–40 mmHg) or abdominal binders are most effective, as lower-extremity-only compression fails to prevent splanchnic venous pooling. Compression should be donned before standing
- Physical countermanoeuvres: Leg crossing, muscle tensing, squatting, and toe raises during prolonged standing increase venous return. These are immediate, cost-free interventions that patients can use in any setting
- Positional strategies: Avoid prolonged standing; use a stool or perching seat for kitchen and bathroom activities. Elevate the head of the bed by 10–15 cm (not pillows alone, which flex the neck without changing hemodynamics) to reduce nocturnal natriuresis and improve morning orthostatic tolerance
- Graded reconditioning: If tolerated within the energy envelope, recumbent exercise (recumbent cycling, swimming, rowing) can maintain cardiovascular function and prevent orthostatic deconditioning without the orthostatic stress of upright exercise. The Dallas/Leeds POTS protocol provides a clinical precedent from an adjacent condition: seated rowing, recumbent cycling, and swimming as starting modalities, with documented cardiovascular benefits in POTS patients (Fu et al. 2010) (Fu and Levine 2018) — however, the protocol has not been tested in ME/CFS, and community completion drops to 41 percent from 76 percent in research settings. The goal is maintenance, not fitness improvement — progression must be extremely gradual and must not trigger PEM (see Section Exercise Precautions for the fitness-maintenance framework and Section Water Rowing as a POTS/ME/CFS-Tolerable Modality — Constant Position + Hydrostatic Pressure + Compound Distribution for land-based rowing)
2 Medications
When non-pharmacological measures are insufficient, medications targeting specific orthostatic mechanisms are added sequentially:
- Fludrocortisone: 0.05–0.2 mg daily. A mineralocorticoid that increases plasma volume through sodium and water retention. Monitor for hypokalemia, edema, and supine hypertension. First-line pharmacological agent for NMH
- Midodrine: 2.5–10 mg two to three times daily (last dose at least 4 hours before bedtime). An alpha-1 agonist that increases peripheral vascular resistance. Monitor for supine hypertension (check supine BP at peak effect — 1 hour post-dose — at treatment initiation and dose changes), piloerection, and urinary retention. Particularly effective for orthostatic hypotension. Kwok et al. (2026) conducted a systematic review and meta-analysis of 14 studies (n=968) finding midodrine significantly increases symptom response vs placebo in pediatric POTS (RR 1.52, 95% CI 1.15–2.00, p=0.01), with hypertension in 8.2% of patients (severity and clinical consequences of this hypertension were not reported) (Kwok et al. 2026). Evidence in adults is limited, heterogeneity was substantial (I²=78%), and no ME/CFS-specific trial data exist. Midodrine is considered second- or third-line therapy after non-pharmacological measures and volume expansion, based primarily on pediatric POTS evidence extrapolated to adults.
- Pyridostigmine: 30–60 mg two to three times daily. An acetylcholinesterase inhibitor that enhances ganglionic neurotransmission, modestly increasing standing blood pressure without supine hypertension. Well-tolerated; GI side effects (nausea, diarrhea) may limit dose
- Beta-blockers: Low-dose propranolol (10–20 mg two to three times daily) for POTS with prominent tachycardia. Propranolol may worsen fatigue and exercise intolerance
- Droxidopa: 100–600 mg three times daily. A norepinephrine prodrug for neurogenic orthostatic hypotension. May be particularly relevant given the CSF catecholamine deficiency documented by Walitt et al. (Chapter Mechanistic and Experimental Studies)
- Ivabradine: 2.5–7.5 mg twice daily. Selectively reduces heart rate without affecting blood pressure. May be appropriate for hyperadrenergic POTS with normal/high stroke volume. Caution in low-SV POTS: HR reduction without SV support risks worsening cardiac output and cerebral perfusion (Chapter Cardiovascular Dysfunction, Speculation Compensatory Tachycardia in POTS — HR Reduction as CBF Destabilization). No ME/CFS-specific trial data exist.
- Mestinon + midodrine combination: Combining pyridostigmine (parasympathetic augmentation) with midodrine (sympathetic augmentation) can address both limbs of the autonomic deficit